CytoTronics Analysis: $23M Raised
What is CytoTronics?
CytoTronics commercializes technology from Harvard University labs to enable live-cell function visualization at scale. Pixel™ systems deliver simultaneous readouts of viability, morphology, electrophysiology, and metabolism. The platform supports any cell model including spheroids and 3D organoids with single-cell resolution and full assay scalability.
Location
Boston, United States
Employees
11-50
Founded
2020
Funding Status
Seed
Product Features & Capabilities
- Pixel™ systems for live-cell monitoring
- Simultaneous readouts of viability, morphology, electrophysiology, and metabolism
- Single-cell resolution with spatial images and longitudinal videos
- Full assay scalability from single plate to industrial scale
- Cloud-based software for data analysis
Use Cases
Monitor cell viability and morphology in vascular biology experiments; Track electrophysiological changes in cardiac cells under drug exposure; Assess metabolic responses in 3D organoids during disease modeling; Evaluate stem cell differentiation in real time; Screen drug candidates for neurological diseases using neural application; Validate therapeutic efficacy in oncology models with longitudinal data
Other Considerations
Launched neural application for neurological disease screening in April 2025; Expanded multi-modal cardiac application for cardiovascular drug screening in May 2025; Partnerships with academic research institutions; Published peer-reviewed publications in leading journals; Case studies available for key therapeutic areas
See something that needs updating? Suggest edits to this profile.